Paul A Gastañaduy1, Andrew P Steenhoff2, Margaret Mokomane3, Mathew D Esona1, Michael D Bowen1, Haruna Jibril4, Jeffrey M Pernica5, Loeto Mazhani6, Marek Smieja7, Jacqueline E Tate1, Umesh D Parashar1, David M Goldfarb8. 1. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Department of Paediatrics and Adolescent Health, University of Botswana Botswana-UPenn Partnership, Gaborone Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine. 3. Department of Medical Laboratory Sciences, University of Botswana and National Health Laboratory. 4. Botswana Ministry of Health, Gaborone. 5. Division of Infectious Disease, Department of Pediatrics, McMaster University, Hamilton, Canada. 6. Department of Paediatrics and Adolescent Health, University of Botswana Department of Pediatrics, Princess Marina Hospital, Gaborone, Botswana. 7. Department of Pathology and Molecular Medicine, McMaster University, Hamilton. 8. Department of Paediatrics and Adolescent Health, University of Botswana Botswana-UPenn Partnership, Gaborone University of British Columbia, Vancouver, Canada.
Abstract
BACKGROUND: Botswana introduced monovalent G1P rotavirus vaccine (RV1) in July 2012, providing one of the first opportunities to assess the effectiveness of routine RV1 vaccination in a high-burden setting in Africa. We sought to determine the effectiveness of RV1 against rotavirus diarrhea hospitalization using a case-control evaluation. METHODS: Vaccine age-eligible children <5 years of age admitted with diarrhea at 4 hospitals in Botswana were enrolled from June 2013 to April 2015. Card-confirmed vaccine history was compared between case patients (children with laboratory-confirmed rotavirus diarrhea) and nonrotavirus "test-negative" diarrhea controls. Vaccine effectiveness (VE) was computed using unconditional logistic regression models adjusting for age, birth month/year, and hospital. Sequence-based genotyping was performed on antigen-positive samples. RESULTS: Among 242 case patients and 368 controls, 82% (199/242) and 92% (339/368), respectively, had received ≥1 doses of RV1. Effectiveness of a full series (2 doses) of RV1 against rotavirus diarrhea requiring hospitalization was 54% (95% confidence interval [CI], 23%-73%); 1 dose of RV1 was 48% (95% CI, 1%-72%) effective. Effectiveness was 59% (95% CI, 4%-83%) against rotavirus caused by G2P, the most common (37%) circulating genotype. However, the effectiveness of 2 RV1 doses was significantly higher in children with no undernutrition (VE, 75% [95% CI, 41%-89%]), compared to those with moderate or severe undernutrition (VE, -28% [95% CI, -309% to 60%]) (P= .02). CONCLUSIONS: Routine RV1 vaccination in Botswana showed effectiveness similar to that in clinical trials in Africa, including against a serotype fully heterotypic to the vaccine. Undernutrition may in part explain the lower rotavirus VE in low-income settings.
BACKGROUND: Botswana introduced monovalent G1P rotavirus vaccine (RV1) in July 2012, providing one of the first opportunities to assess the effectiveness of routine RV1 vaccination in a high-burden setting in Africa. We sought to determine the effectiveness of RV1 against rotavirus diarrhea hospitalization using a case-control evaluation. METHODS: Vaccine age-eligible children <5 years of age admitted with diarrhea at 4 hospitals in Botswana were enrolled from June 2013 to April 2015. Card-confirmed vaccine history was compared between case patients (children with laboratory-confirmed rotavirus diarrhea) and nonrotavirus "test-negative" diarrhea controls. Vaccine effectiveness (VE) was computed using unconditional logistic regression models adjusting for age, birth month/year, and hospital. Sequence-based genotyping was performed on antigen-positive samples. RESULTS: Among 242 case patients and 368 controls, 82% (199/242) and 92% (339/368), respectively, had received ≥1 doses of RV1. Effectiveness of a full series (2 doses) of RV1 against rotavirus diarrhea requiring hospitalization was 54% (95% confidence interval [CI], 23%-73%); 1 dose of RV1 was 48% (95% CI, 1%-72%) effective. Effectiveness was 59% (95% CI, 4%-83%) against rotavirus caused by G2P, the most common (37%) circulating genotype. However, the effectiveness of 2 RV1 doses was significantly higher in children with no undernutrition (VE, 75% [95% CI, 41%-89%]), compared to those with moderate or severe undernutrition (VE, -28% [95% CI, -309% to 60%]) (P= .02). CONCLUSIONS: Routine RV1 vaccination in Botswana showed effectiveness similar to that in clinical trials in Africa, including against a serotype fully heterotypic to the vaccine. Undernutrition may in part explain the lower rotavirus VE in low-income settings.
Authors: Margaret Mokomane; Jacqueline E Tate; Andrew P Steenhoff; Mathew D Esona; Michael D Bowen; Kwana Lechiile; Jeffrey M Pernica; Ishmael Kasvosve; Umesh D Parashar; David M Goldfarb Journal: Pediatr Infect Dis J Date: 2018-03 Impact factor: 2.129
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Joann F Gruber; Sylvia Becker-Dreps; Michael G Hudgens; M Alan Brookhart; James C Thomas; Michele Jonsson Funk Journal: Epidemiology Date: 2018-11 Impact factor: 4.822
Authors: N A Page; L M Seheri; M J Groome; J Moyes; S Walaza; J Mphahlele; K Kahn; C N Kapongo; H J Zar; S Tempia; C Cohen; S A Madhi Journal: Vaccine Date: 2017-10-27 Impact factor: 3.641